Abstract : At first, hybridoma technique was used to create murine antibodies (ending in -omab). However, these antibodies fail in clinical trials because of the significant differences between the human and mouse immune systems. When given repeatedly, murine antibodies cause minor allergic responses and even anaphylactic shock in humans (HAMA). The host swiftly rids itself of these therapeutic HAMA antibodies. Immune complexes are also formed, and these can cause harm to the kidneys. In an effort to lessen the immunogenicity of murine antibodies, highly effective antibodies were produced by removing their immunogenic component from murine sources.
